Related Experiment Videos

Effects of one year simvastatin and atorvastatin treatments on acute phase reactants in uncontrolled type 2 diabetic

Kubilay Ukinc1, Halil Onder Ersoz, Cihangir Erem

  • 1Department of Endocrinology and Metabolism, Karadeniz Technical University, Trabzon, Turkey. kukinc@comu.edu.tr

Endocrine
|March 5, 2009
PubMed

Insights

Atorvastatin and simvastatin effectively reduced cholesterol and inflammatory markers like hsCRP, fibrinogen, and ferritin in type 2 diabetes patients over one year. Both statins improved cardiovascular risk factors in uncontrolled diabetes.

Area of Science:

  • Cardiology
  • Endocrinology
  • Pharmacology

Background:

  • Type 2 diabetes mellitus is a primary driver of macrovascular complications and mortality.
  • Diabetic patients often present with multiple cardiovascular risk factors, including hypercholesterolemia, hypertension, obesity, and inflammation.
  • Inflammatory markers play a crucial role in the pathogenesis of diabetic macrovascular complications.

Purpose of the Study:

  • To evaluate and compare the one-year effects of atorvastatin versus simvastatin on inflammatory markers (hsCRP, fibrinogen, ferritin) in type 2 diabetic patients.
  • To investigate the correlation between these inflammatory markers and metabolic parameters in the studied population.

Main Methods:

  • Fifty type 2 diabetic patients and twenty healthy controls were enrolled.
  • Diabetic patients were randomized to receive either atorvastatin or simvastatin for one year.
  • Measurements included lipid profiles, hsCRP, fibrinogen, and ferritin levels, analyzed at baseline and after treatment.

Main Results:

  • Both atorvastatin and simvastatin significantly reduced total cholesterol, LDL-cholesterol, hsCRP, fibrinogen, and ferritin levels compared to baseline values.
  • Significant decreases in hsCRP, fibrinogen, and ferritin were observed in both treatment groups after one year.
  • Inflammatory markers (hsCRP, fibrinogen, ferritin) showed significant correlations with LDL and HDL cholesterol levels at the end of the study.

Conclusions:

  • Atorvastatin and simvastatin are effective in managing hypercholesterolemia in type 2 diabetic patients.
  • Statin therapy leads to a significant reduction in key acute-phase reactants, contributing to improved cardiovascular risk profiles in uncontrolled type 2 diabetes.

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...